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ABSTRACT
Although derived from the host tissue, the tumor vasculature is under
the influence of the tumor microenvironment and needs to adapt to the
resistance to blood flow inherent to the dynamics of tumor growth. Such
vascular remodeling can offer selective targets to pharmacologically mod-
ulate tumor perfusion and thereby improve the efficacy of conventional
anticancer treatments. Radiotherapy and chemotherapy can, indeed, take
advantage of a better tumor oxygenation and drug delivery, respectively,
both partly dependent on the tumor blood supply.
Here, we showed that isolated tumor arterioles mounted in a pressure
myograph have the ability, contrary to size-matched healthy arterioles, to
contract in response to a transluminal pressure increase. This myogenic
tone was exquisitely dependent on the endothelin-1 pathway because it
was completely abolished by the selective endothelin receptor A (ETA)
antagonist BQ123. This selectivity was additionally supported by the large
increase in endothelin-1 abundance in tumors and the higher density of
the ETA receptors in tumor vessels. We also documented by using laser
Doppler microprobes and imaging that administration of the ETA antag-
onist led to a significant increase in tumor blood flow, whereas the
perfusion in control healthy tissue was not altered. Finally, we provided
evidence that acute administration of the ETA antagonist could signifi-
cantly stimulate tumor oxygenation, as determined by electron paramag-
netic resonance oximetry, and increase the efficacy of low-dose, clinically
relevant fractionated radiotherapy.
Thus, blocking the tumor-selective increase in the vascular endothelin-1/
ETA pathway led us to unravel an important reserve of vasorelaxation that
can be exploited to selectively increase tumor response to radiotherapy.
INTRODUCTION
The tumor vasculature has unique features, which may be viewed as
many selective targets for anticancer strategies. Accordingly, the last
15 years have witnessed the development of drugs targeting tumor
vessels, namely the antiangiogenic (1, 2) and antivascular agents (3).
Although the goals of these approaches are different (e.g., to prevent
new blood vessel formation and to occlude/destroy pre-existing ves-
sels, respectively), they both exploit the specific phenotype of endo-
thelial cells lining tumor blood vessels to selectively target tumor
perfusion (4). An interest also simultaneously developed for opposite
strategies aiming to enhance the tumor perfusion (5, 6). The rationale
for such qualitative improvement in the function of tumor blood
vessels is to increase the efficacy of radio- or chemotherapy (7, 8).
This concept implies that the effects on tumor blood flow need to be
transient and selective. Although the action of vasomodulatory drugs
can be controlled by adapting their protocol of administration, the
selectivity issue is limiting and matter of investigation (9).
We and others have reported that drugs like nitric oxide donors (10,
11), nicotinamide (12), bradykinin agonist (13), and insulin (14), but
also radiations and chemotherapeutic agents themselves (15–17),
could modulate tumor blood flow, oxygenation, and permeability,
thereby optimizing associated antitumor treatments. The validity of
these adjuvant approaches to conventional chemo- and radiotherapy
was usually verified a posteriori by documenting a better tumor
response with very limited insights on the mechanisms of the tumor
selectivity. Conversely, studies that did not look for a gain in treat-
ment efficacy have identified the existence of tumor-specific vascular
reactivity to various products including endothelin (18), endothelin
agonist (19), angiotensin (20, 21), noradrenaline (22), hemoglobin A
(23), and tumor necrosis factor  (24).
We reasoned that the identification of vasomodulatory pathways truly
selective of the tumor vasculature could arise from the ex vivo compar-
ison of the intrinsic pharmacological reactivity of vessels issued either
from tumors or from the tumor-hosting tissues. Indeed, the variety of
chemokines and cytokines released by tumor cells are known to trigger
regulatory processes within the tumor vasculature leading to phenotypic
shift including escape from immunosurveillance and adaptation to hy-
poxia (2, 25, 26). Therefore, it was very likely that the tumor microen-
vironment could also, directly or indirectly, induce profound alterations in
the tumor vessel reactivity. Accordingly, using a myograph (originally
dedicated to study the physiopathology of normal arterioles), we reported
recently that the acetylcholine-induced nitric oxide-mediated vasodilation
was dramatically altered in tumor arterioles (15). Also, in the same study,
we documented how ionizing radiations by reversing the lack of NO-
mediated response of tumor vessels could increase the sensitivity of the
tumor to further X-ray fractions (15).
In the current study, our reflection started from the growing evidence
that endothelin-1 production is increased in many tumor types where it
plays crucial roles in proliferation and angiogenesis (27–29). In these
studies, however, there was no mention of the powerful vasoconstrictive
effects of endothelin-1 (ET-1) and its potential action on the contractile
tone of tumor vessels. Indeed, although ET-1 can induce vasodilation
through activation of the endothelin receptor B (ETB), a powerful vaso-
constriction is obtained when ET-1 interacts with the endothelin receptors
A and B (ETA and ETB) located on smooth muscle cells. In this study, we
therefore asked ourselves whether the tumor production of ET-1 could
influence local vascular tone and whether blocking ET-1 signaling could
have an impact on tumor blood flow and thereby be exploited to promote
conventional antitumor therapy.
MATERIALS AND METHODS
Mice. NMRI, C57BL/6J, and C3H/He male mice (Elevage Janvier, Le
Genest-St-Isle, France) were used in experiments with transplantable liver tumor
(TLT; mouse hepatocarcinoma; Ref. 30), Lewis Lung carcinoma (mouse lung
carcinoma; Ref. 31), and Fibrosarcoma-II (mouse fibrosarcoma; Ref. 32) synge-
neic tumor cells, respectively. Anesthetized mice (ketamine/xylazine) received
i.m. injections of 105-106 tumor cells in the vicinity of the saphenous arteriole of
the posterior right leg. The pre-existing arteriole was progressively co-opted as the
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tumor grew (see Fig. 1G). The tumor diameters were tracked with an electronic
caliper. When the tumor diameter reached 4.0 0.5 mm, mice were sacrificed or
randomly assigned to a treatment group. When indicated, they received an i.p.
injection of the selective ETA antagonist BQ123 (0.5, 1, and 2 mg/kg; Sigma,
Bornem, Belgium) or saline alone. Each procedure was approved by the local
authorities according to national animal care regulations.
Immunoblottings and Immunostainings. Immunoblottings were carried
out, as described previously (15, 33), with a sheep polyclonal antibody against
ETA (Abcam, Cambridge, United Kingdom) or ETB (Alomone Labs, Jerusa-
lem, Israel). For immunostainings, collected tissue samples were cryosliced
and probed with a rabbit polyclonal antibody against ET-1 (gift from Ronald
van Beneden, University of Louvain, Brussels, Belgium; Ref. 34). Endogenous
peroxidase activity was inhibited by 0.3% H2O2 in PBS, and Envision system
(Dako, Glostrup, Denmark) was used for revelation. Sections were finally
counterstained with Mayer’s hematoxylin. Quantitative image analyses of
immunostained arteriole slices (5 arterioles/condition and 3 sections/animal)
were performed with AnalySIS software (Soft Imaging System, Mu¨nster,
Germany).
Myograph Assays. Tumor saphenous arterioles and size-matched arte-
rioles from healthy mice were dissected under a stereoscopic microscope and
mounted on a 110P pressure myograph (DMT, Aarhus, Denmark). No mac-
roscopic differences were detectable between the tumor and control arterioles
(diameters of 284  14 and 299  17 m, respectively; P  0.1). Changes in
the outer diameters were tracked and measured with the Myoview software
(DMT). To evaluate the myogenic tone, isolated arterioles were left to recover
for 45–60 min in no-flow condition (20 mm Hg; 37.5°C). Then, the pressure
was increased by steps of 20 mm Hg (that were maintained for 15 min to allow
arteriole response). For each pressure step, the active vessel diameter was
determined in physiological salt solution buffer (NaCl 119 mM, KCl 4.7 mM,
NaHCO3 25 mM, KH2PO4 1.18 mM, MgSO4 1.17 mM, EDTA 0.026 mM,
glucose 5.5 mM, and CaCl2 1.6 mM); then the passive diameter of the same
arteriole was measured in CaCl2-deprived physiological salt solution supple-
mented with 10 M sodium nitroprusside and 2 mM EGTA. In some experi-
ments, the active diameter was determined after a 60-min preincubation in the
calcium-containing physiological salt solution buffer with BQ123 (1 M).
For the establishment of the ET-1 dose-response curve, isolated arterioles were
left to recover at physiological pressure for 45–60 min in no-flow condition in
physiological salt solution medium (60 mm Hg, 37.5°C); additive doses of ET-1
(Sigma) were then delivered in the bathing medium. For each vessel used in this
study, the ability of the vessels to contract upon application of a depolarizing KCl
solution was verified at the end of the experiment and compared with a similar
contraction performed at the very beginning of the experiment. If these two
contractions differed by 10%, the experiment was disregarded.
Tumor Blood Flow Monitoring. Tumor perfusion was measured with a
Laser Doppler imager (Moor Instruments) and with Laser Doppler micro-
probes (Oxyflo; Oxford Optronix). Briefly, for the Laser Doppler imaging
measurements, mice were anesthetized and fur was removed from the limbs
using a depilatory cream. They were placed on a heating pad (37°C) to
minimize variations in temperature. The average perfusions of the tumor-
bearing leg and of the control leg were evaluated on the basis of colored
histogram pixels. For the Oxyflo measurements, fiber-optic microprobes (La-
ser Doppler  thermocouple) were introduced into the tumor. Back scattering
measurements were used to validate the absence of movement artifacts. A
10-min baseline of stable recordings was obtained before treatment adminis-
tration through the catheterized tail vein; data were collected continuously at a
sampling frequency of 20 Hz.
Electron Paramagnetic Resonance (EPR) Oximetry. This real-time, O2-
nonconsuming technique was used to track the changes in pO2 induced by
BQ123 administration. EPR oximetry relies on the oxygen-dependent broad-
ening of the EPR linewidth of a paramagnetic oxygen sensor preimplanted in
the tumor. Accordingly, 50 l of a suspension (100 mg/ml) of the O2-sensitive
probe (charcoal wood powder, CX0670–1; EM Science, Gibbstown, NJ) were
injected in the center of the tumor 24 h before X-ray irradiation, as described
previously and validated (10, 14, 15). The tumors of anesthetized mice were
placed in the center of the surface coil. EPR spectra were recorded using an
Fig. 1. Immunodetection of endothelin-1 (ET-1) in tumor and
tumor vessels. ET-1 antibodies were used to immunostain (A) car-
diac tissue from healthy mice (cl indicates the lumen of a coronary
artery); (B) transplantable liver tumor; (C) Lewis Lung carcinoma
tumor; and (D) Fibrosarcoma-II tumor. ---- delineate the healthy
muscular tissue (m) surrounding tumors or the central necrotic core
(nc). Bar  100 m. Saphenous arterioles from (E) healthy or (F)
tumor-bearing mice were also immunostained for ET-1 expression.
G, shown is the anatomical location of the saphenous arteriole
located between the saphenous vein (v) and nerve (n); the ---- shows
the limits of the tumor and the arrowhead indicates where the
arteriole enters the tumor (e.g., where arterial segments were iso-
lated for myograph studies).
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EPR spectrometer (Magnettech, Berlin, Germany) with a low frequency mi-
crowave bridge operating at 1.1 GHz and extended loop resonator.
Radiotherapy and Tumor Measurements. Anesthetized TLT tumor-
bearing mice were irradiated using the RT-250 device (Philips) for a dose
delivery of 0.76 Gy/min. Mice were shielded with lead except for a 3-cm-
diameter circular field where the tumor was centered. When indicated, mice
received an i.p. injection of 1 mg/kg BQ123 or saline alone, 45-min before
each dose delivery. Tumor-bearing and control legs were daily measured with
an electronic caliper, the difference corresponding to the tumor diameter. Mean
regrowth delays refer to the doubling of the tumor diameters.
Statistical Analyses. Data are reported as mean  SE; Student’s t test or
two way ANOVA were used where appropriate. To determine synergism, we
compared tumor doubling times using a nonparametric Mann-Whitney analy-
sis; a generalized linear model with two-way ANOVA was also applied and led
to similar results.
RESULTS
Expression of ET-1 in Tumor Cells and in the Tumor Vascu-
lature. We first characterized the ET-1 production in 3 syngeneic tumor
models (TLT, Lewis Lung carcinoma, and Fibrosarcoma-II) obtained by
i.m. injections of tumor cells. When reaching a diameter of 4.0  0.5
mm, the tumors were resected and processed for immunostaining with
ET-1 antibodies; mouse heart was used as control for antibody specificity
(see Fig. 1A). As shown in Fig. 1, B–D, the different tumors were found
to produce large amounts of ET-1 that were detectable both inside the
tumor cells and in the extracellular space. Very low amounts of ET-1
were found in the healthy surrounding muscular tissues (see Fig. 1, B and
C) and in the necrotic core of the tumor (see Fig. 1D). Importantly, the
co-opted tumor vasculature was strongly labeled, revealing a 13-fold
increase (P  0.05; n  15) in ET-1 in the vessel wall when compared
with control size-matched arterioles (Fig. 1, E and F).
Differential Reactivity of Tumor Arterioles to ET-1. To evaluate
the vasomodulatory effects of the increased ET-1 concentrations in tumor
arterioles, we isolated TLT-co-opted arterioles (see Fig. 1G) and size-
matched arterioles from healthy animals. These arterioles were mounted
on a pressure myograph, and after pressurization and equilibration, ex-
posed to increasing doses of ET-1. In arterioles from healthy mice, low
ET-1 concentrations (1013-1010 M) were ineffective, whereas higher
doses (109-107 M) dose-dependently constricted the vessels (Fig. 2A).
By contrast, tumor-co-opted arterioles contracted with ET-1 concentra-
tions as low as 1011 M (Fig. 2A) and reached a maximum at 108 M
ET-1 (the maximum contraction was obtained at 107 M ET-1 in control
vessels). Calculated EC50s were 0.40 nM and 2.01 nM (P  0.05; n  5)
in tumor and in size-matched healthy arterioles, respectively. Immunob-
lots performed on carefully microdissected arterioles (cleaned from sur-
rounding tissues) also revealed that the density of ETA (e.g., the ET-1
receptor mediating vasoconstriction) was increased by 5-fold in co-opted
vessels versus healthy arterioles (Fig. 2B). Interestingly, when using total
lysates from tumors, we failed to detect ETA receptor by immunoblotting
suggesting a weaker density of this receptor in tumor cells than in
vascular cells.
The density of ETB receptors was not significantly altered in
co-opted tumor arterioles (Fig. 2B), and immunohistochemistry re-
vealed that most of the ETB signal was concentrated in the endothelial
layer of the arterioles (data not shown).
Tumor Arterioles Exhibit a Myogenic Tone Sensitive to an ETA
Antagonist. Because we have identified that tumor arterioles are
chronically exposed to large amounts of ET-1 (see Fig. 1) and are
(remain) hyper-responsive to ET-1 (see Fig. 2), we next examined
whether intrinsic features of tumor arterioles were under the tonic
control of this pathway. Accordingly, we examined the presence in
tumor arterioles of a differential myogenic tone (i.e., the ability of
arterioles to contract when the intraluminal pressure increases; Ref.
35). Myogenic vasoconstriction is, indeed, thought to provide a level
of basal tone that enables arterioles to respond to neurohumoral
stimuli with the appropriate changes in vessel diameter.
Using a pressure myograph, we examined the response of isolated
tumor-co-opted and control arterioles to step-by-step increases of the
luminal pressure. Accordingly, the changes in the active diameter
(measured in calcium-containing medium) and in the passive diameter
(determined in a medium devoid of calcium) were consecutively
tracked for each arteriole. In healthy mice, no myogenic tone was
observed: both the active and the passive diameters increased simi-
larly when the pressure raised (Fig. 3A). By contrast, tumor-co-opted
arterioles were able to respond to the pressure increase by a vasocon-
striction (detected as a lesser vasodilation) in calcium-containing, but
not in calcium-deprived medium (Fig. 3B), thereby acknowledging
the existence of an intrinsic myogenic tone.
We then investigated the implication of the ET-1/ETA pathway in
the myogenic tone of TLT tumor-co-opted arterioles by using the
specific ETA antagonist BQ123. The effect of the preincubation with
BQ123 was dramatic, because it completely abrogated the myogenic
tone (Fig. 3B; P 0.01). In fact, the active diameter curve under ETA
inhibition (Fig. 3B, black triangles) was not different from the passive
diameter curve (Fig. 3B, open circles). As a control, we also demon-
strated that ETA inhibition left unaffected the active diameter of
size-matched arterioles from healthy mice (Fig. 3A).
ETA Inhibition Triggers a Tumor-Specific Increase in Blood
Flow and Oxygenation. We then investigated whether the BQ123-
mediated abrogation of the myogenic tone (as elicited ex vivo) was
correlated with an increased tumor perfusion in vivo. Accordingly, TLT
tumor-bearing mice received a bolus i.p. injection of 1 mg/kg BQ123 or
saline, and the perfusion of both the tumor-bearing and the control legs
was monitored using a Laser Doppler imaging system. In BQ123-treated
mice, we consistently observed an important increase in the blood flow of
the tumor-bearing leg (Fig. 4A, top panel, white circle), whereas the
healthy opposite leg failed to show any significant changes in perfusion
(Fig. 4A, top panel, white arrows). Importantly, isovolemic saline i.p.
injection barely increased the basal perfusion in the tumor-bearing leg
(see Fig. 4A, lower panels, and Fig. 4B). We also used Laser Doppler
needle probes directly introduced in the tumors to validate the results
Fig. 2. Tumor arterioles are hyper-responsive to endothelin-1 (ET-1) and overexpress
smooth muscle endothelin receptor A (ETA) receptor. A, arterioles isolated from healthy
() and from transplantable liver tumor-bearing mice (f) were mounted on a pressure
myograph and exposed to increasing doses of ET-1. Results are expressed as percentage
of the maximal contraction obtained with 107 M ET-1. Sigmoidal fitting shows that the
dose/effect curves for healthy and tumor vessels (R2  0.91 and 0.98, respectively) were
significantly different (P  0.01; n  5); note that some SE are smaller than symbols;
bars,SE. B, pools of arterioles from healthy and transplantable liver tumor-bearing mice
were lysed (to obtain enough material) and were immunoblotted with endothelin receptor
A (ETA) and endothelin receptor B (ETB) antibodies. Shown are representative immuno-
blots and a bar graph depicting the densitometric analysis of two different immunoblots
(2 pools of 10 arterioles/condition).
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obtained with the imager. A similar increase in blood flow was observed
after BQ123 administration (Fig. 4C).
Using EPR oximetry, we also evaluated the BQ123-induced
changes in tumor pO2. Fig. 4D shows that 60 min after administration
of the ETA antagonist (but not of the saline solution), the tumor
oxygenation was significantly increased over basal level (174%;
P 0.01; n 7). Of note, the measured pO2 corresponds to the mean
value in a tumor volume of 10 mm3 (i.e., the volume of charcoal
dispersion as determined by histology) and, therefore, does not pre-
clude more dramatic variations in specific regions of the tumor.
ETA Inhibition Radiosensitizes Tumors. In various tumor mod-
els, improved tumor perfusion is associated with a net increase in
tumor oxygenation, which may be exploited to increase the effective-
ness of radiotherapy (10, 14, 15). Therefore, we tested the hypothesis
that ETA inhibition could radiosensitize tumors. Accordingly, we
daily determined the tumor diameters of mice receiving (or not)
fractionated radiotherapy, and evaluated the effects of BQ123 admin-
istered 45 min before each radiation fraction (to have the maximum
increase in pO2 at the time of X-ray exposure; see Fig. 4). As shown
in Fig. 5, A and B, and Table 1, when fractionated radiotherapy (5 2
Gy and 2  6 Gy) was combined to the BQ123 pretreatment, the
overall benefit on tumor growth retardation was higher than the sum
of the effects of the two treatments administered separately (P 0.01;
n  8–11). Similar data were obtained with two other tumor models,
namely Lewis Lung carcinoma tumors and Fibrosarcoma-II (data not
shown); both tumor types overexpress ET-1 (see Fig. 1, C and D) and
arterioles issued from the former were shown to also exhibit myogenic
tone (data not shown).
A dose-response curve was also generated using three different
doses of BQ123 (0.5, 1, and 2 mg/kg) in combination with the 2  6
Gy protocol (Fig. 5C). Although limitations in BQ123 availability
precluded additional exploration, it is noteworthy that with the higher
dose (2 mg/kg), two mice (of 6) were in remission 5 weeks after
treatment (see Fig. 5 legend). Of note, at each dose used in this study,
BQ123 (two or five i.p. injections) only slightly restrained tumor
growth by itself (see Fig. 5, A and B, and Table 1).
DISCUSSION
The two major findings of this study are: (a) that basal production
of ET-1 in tumors leads to the development of a myogenic tone that
represents an important reserve for vasorelaxation; and (b) that the use
Fig. 3. Tumor arterioles exhibit an endothelin
receptor A-dependent myogenic tone. Isolated ar-
terioles were mounted on a pressure myograph and
allowed to respond to a step-by-step increase of the
luminal pressure. Changes in vessel diameter were
tracked in bathing media containing calcium (ac-
tive diameter, F; n  10) or not (passive diameter,
E; n  10). Saphenous arterioles were dissected
from healthy mice (A) or were isolated from trans-
plantable liver tumor (after co-option; B). In some
experiments, arterioles were preincubated with the
endothelin receptor A antagonist BQ123 (1 M) in
the calcium-containing medium (active diameter,
Œ; n  3); ns, not significantly different; ,
P 0.01 between the indicated dose/effect curves);
bars, SD.
Fig. 4. Endothelin receptor A inhibition in-
creases tumor blood flow and oxygenation. A,
shown are typical Laser Doppler imaging pictures
obtained before (time 0) and 60 min after i.p.
injection of 1 mg/kg BQ123 (top panels) or vehicle
alone (bottom panels). On each picture, the tumor-
bearing leg is on the right (white circle) and the
control leg on the left (white arrow). B, shown is
the time course of global changes in tumor perfu-
sion (derived from Laser Doppler imaging color
pixel histograms) after BQ123 (F; n  11) or
saline (E; n  10) injection; data are expressed as
percentage of the basal perfusion. (, P  0.01
when comparing the two curves). C, shown is the
time course of local changes in tumor perfusion
determined with Laser Doppler needle microprobes
(Oxyflo) after BQ123 (F) or saline (E) injection
(n  12). Data are expressed as percentage of the
basal perfusion at time 0 (, P  0.01 when
comparing the two curves). D, bar graph represents
the tumor pO2 measured by electron paramagnetic
resonance at baseline (; n  14) and 45 min after
saline (o; n  7) or BQ123 (f; n  7) adminis-
tration (, P  0.01); bars, SD.
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of an ETA antagonist can selectively promote tumor perfusion and
oxygenation, and consecutively increase the effectiveness of tumor
radiotherapy.
The existence of a myogenic tone is almost impossible to quanti-
tatively appreciate in vivo, because it requires the tracking of changes
in vascular resistance in response to an increase in transmural pres-
sure. Here, we used a unique experimental model specifically dedi-
cated to this purpose, e.g., microdissected tumor vessels mounted in a
myograph allowing step increases in pressure. This ex vivo mode of
detection should not mask the in vivo importance of the myogenic
tone in the autoregulation of blood flow by arterioles. Indeed, in
normal vascular beds, spontaneous (oscillating) and pressure-induced
variations in the muscular tone, known as vasomotion (36) and myo-
genic tone (35, 37), respectively, offer to the tissue circulation the
intrinsic ability to maintain a relatively constant blood flow despite
variations in blood pressure. In the case of tumors, such autoregula-
tory mechanisms are very likely to be needed to face the constant
remodeling of tumor vascularization. Here, we have identified the
implication of ET-1 as a trigger of the myogenic tone of tumor
vessels. The signal transduction appears to transit through the smooth
muscle-specific ETA receptor (the abundance of which is increased by
5-fold in tumor arterioles) because BQ123 (a specific ETA antagonist)
completely abrogated the pressure-dependent development of vascu-
lar tone by tumor arterioles.
That the implication of the ET-1/ETA pathway in the development of
a myogenic tone is specific of the tumor vascular bed was additionally
authenticated by the increase in blood flow observed after treatment with
BQ123 in tumors but not in control tissue from the same mouse (see Fig.
4). Interestingly, ET-1 has been shown to exert its vasoconstrictive effects
when applied from the adventitial side of the vessels (38, 39), which in
the case of ET-1-producing tumors is very likely to account for local
(specific) effects. Moreover, we found an increased vascular ETA expres-
sion in tumor arterioles, which is also very likely to contribute to the
observed myogenic tone. Exaggerated production of ET-1 has been
reported previously to mediate similar increase in myogenic constriction
in cerebral arteries exposed to oxidized low-density lipoprotein (40) and
arterioles isolated from hypertensive rats (41). Together with our study,
these reports indicate that pathological states such as atherosclerosis,
hypertension, and tumor growth can transform vessels devoid of myo-
genic tone in vessels prone to blood flow autoregulation. Of note, the
phenotype shift can be considered as yet more dramatic for tumor vessels,
because we used vessels with an external diameter of 300 m, which is
higher than the usually accepted diameter for resistance arterioles (170
m).
The observed ex vivo and in vivo vasodilating effects of BQ123
imply that functional smooth muscle cells are the target of this drug in
tumor vessels. The presence of smooth muscle cells or mural cells on
vessels is viewed as a hallmark of maturation (42), and it is generally
accepted that month/year-old human tumors are more likely to recruit
pericytes on a larger proportion of their vasculature (versus rapidly
growing mouse tumors). This suggests that functional tumor vessels
constitute a yet more attractive target for selective vasomodulatory
treatments in humans. Although additional studies are required to
evaluate how our data can be extrapolated in the clinics, the tumor
vessel selectivity of ETA antagonist treatment, as identified in mouse,
offers strong bases for the establishment of an adjuvant strategy
aiming to increase the effectiveness of conventional antitumor treat-
Table 1 Mean regrowth delays for TLTa tumors as a function of ionizing radiation
exposure(s) and BQ123 treatment(s)
When indicated (), BQ123 was delivered i.p. 45 min before each irradiation (2 or 6











 0 4.1  0.7  11
 5  2 Gy 8.5  0.6 4.4  0.8 11
 5  0 Gy 4.6  0.3 0.5  0.7 11
 5  2 Gy 13.6  0.7 9.5  0.8 11
 2  6 Gy 13.2  0.9 9.1  0.9b 11
 2  0 Gy 4.6  0.4 0.5  0.8 11
 2  6 Gy 23.0  1.4 18.9  0.8b 8
a TLT, transplantable liver tumor.
b P  0.01, versus additive effects of BQ123 and X-ray administered separately.
Fig. 5. Endothelin receptor A inhibition radio-
sensitizes tumors. Growth of transplantable liver
tumors was determined by measuring tumor diam-
eters in untreated mice (), in mice treated with 1
mg/kg BQ123 alone (f), with irradiation and ve-
hicle (E), and with the combination of irradiation
and BQ123 (F). Irradiated mice received either (A)
five fractions of 2 Gy (day 0 to day 4) or (B) two
fractions of 6 Gy (day 0 to day 1); data are
expressed as percentage of the initial tumor diam-
eters (n  8–11). C, for the 2  (6GyBQ123)
condition, three doses of BQ123 were tested (0.5,
1, and 2 mg/kg), and mean tumor doubling times
were determined (, P 0.01; n 6–8). Of note,
the beneficial effect of the 2 mg/kg dose is under-
estimated because the doubling time was not deter-
mined for 2 mice (of 6), which were in complete
remission 5 weeks after the initiation of treatment.
BQ123 alone (at each dose tested) failed to produce
any significant delay in tumor growth. When coad-
ministered with radiotherapy, BQ123 (or vehicle)
was delivered i.p. 45 min before each irradiation;
bars, SD.
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ments (by acting on tumor blood flow and oxygenation). Adequately
scheduled combination of these latter approaches with antiangiogenic
drugs certainly represents a very attractive area of investigation for
future cancer therapy development.
In this study, we provide evidence that acute administration of
BQ123 (i.e., i.p. injection 45 min before local tumor irradiation) exerts
profound effects on the efficacy of low-dose radiotherapy (5  2 Gy
and 2  6 Gy). Importantly, these effects were shown to be ETA
antagonist dose-dependent and obtained using clinically relevant
schemes of fractionated radiation administration; a complete remis-
sion was even obtained in mice treated with the highest BQ123 dose
tested in this study. Although a small effect of BQ123 alone was
observed in the absence of irradiation (probably attributable to the
antiproliferative effect of this drug; Refs. 27–29), the combination of
both irradiation and the ETA antagonist led to a synergistic effect in
both irradiation protocols, increasing the tumor regrowth delay by
50% over the additive effects (see Table 1). We additionally doc-
umented that the radiosensitizing effects of BQ123 were very likely to
arise from the increase in tumor oxygenation directly associated with
the elevation in tumor blood flow (see Fig. 4).
The growing amounts of reports documenting the increase in ET-1
expression in various human tumors (reviewed in Ref. 29) indicate
that this approach of blocking the ETA receptor opens very interesting
perspectives in the treatment of many tumor types. Moreover, al-
though we have here only documented the impact of modulating the
ET-1/ETA transduction pathway for radiotherapy, it can be postulated
that chemotherapy could also take advantage of a better tumor per-
fusion and drug delivery. Importantly, this study also confirmed the
potential of the myograph assay to identify the existence of a differ-
ential reactivity in arterioles issued from animal tumors characterized
by different environments (see also Refs. 15, 33). This ex vivo
pharmacological evaluation of tumor vessels could easily be extended
to vessels isolated from human tumor biopsies, and thereby could lead
to new insights on “provascular” adjuvant treatments susceptible to
improve conventional anticancer treatments.
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